Dobek Maria 4

What Happened

• Maria Dobek, Vice President, Accounting at Janux Therapeutics (JANX), sold 2,038 shares in an open-market/private sale on May 11, 2026. The shares were disposed at $14.17 each, generating proceeds of approximately $28,878. This was a sale (not a purchase), which is often routine insider liquidity rather than a clear signal of company outlook.

Key Details

• Transaction date: 2026-05-11; Price: $14.17 per share; Total proceeds: ~$28,878.
• Transaction type: Sale (open market or private sale indicated on the Form 4).
• Filing date: 2026-05-13 — filed within the SEC’s two-business-day window (timely).
• Shares owned after the transaction: Not disclosed in the summary provided in your request / not specified in the filing excerpt.
• No footnotes, 10b5-1 plan, tax-withholding, or other special conditions were noted in the provided transaction details.

Context

• Sales by officers can be for many reasons (personal liquidity, diversification, tax planning) and do not necessarily reflect insider sentiment about company prospects. Purchases are generally more informative as affirmative insider buying; this entry is a routine sale by a company officer.